News Quantified

CHRS – coherus biosciences, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Coherus Oncology to Participate in Upcoming Investor Conferences

-10.1%

BEAT

-7.1%

MISS

-19.9%

BEAT

-3.7%

BEAT

Form 10-Q Coherus Oncology, Inc. For: Sep 30

Form 8-K Coherus Oncology, Inc. For: Nov 06

Form SCHEDULE 13G Coherus Oncology, Inc. Filed by: Bering Partners II, L.P.

Form 8-K Coherus Oncology, Inc. For: Sep 05

Top News Gainers

8/1 Q2/2019 6/30/2019 EPS 0.320 ZacksConsensus -0.080 ActVsEst 0.400 - Beat 17.6%

11/6 Form 8-K Coherus BioSciences, For: Nov 06 16.9%

1/13 Form 4 Coherus BioSciences, For: Jan 09 Filed by: HEALY JAMES 14.4%

2/27 Form 8-K Coherus BioSciences, For: Feb 27 13.8%

5/9 Form 8-K Coherus BioSciences, For: May 09 9.6%

3/24 Coherus Biosciences Inc (NASDAQ: CHRS) was upgraded by analysts at TheStreet from a "d+" rating to a "c-" rating. 9.4%

4/20 Coherus Biosciences: Worth The Risks [Seeking Alpha] 7.9%

8/21 Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September 7.0%

3/1 Coherus Biosciences Inc (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $27.00 price target on the stock. 7.0%

3/20 Coherus BioSciences Announces New Employment Inducement Grants 6.5%

Top News Decliners

7/8 Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million -14.3%

5/7 Coherus Biosciences Inc (NASDAQ: CHRS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock. -7.9%

11/25 Form 4 Coherus BioSciences, For: Nov 21 Filed by: Lanfear Dennis M -7.8%

9/25 Form 4 Coherus BioSciences, For: Sep 23 Filed by: Viret Jean-Frederic -7.4%

4/14 Form 8-K Coherus BioSciences, For: Apr 13 -6.4%

5/24 Form 4 Coherus BioSciences, For: May 22 Filed by: HEALY JAMES -5.8%

10/22 Form 4 Coherus BioSciences, For: Oct 18 Filed by: Viret Jean-Frederic -5.5%

3/5 Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020 -5.0%

5/10 Coherus Biosciences Inc (NASDAQ: CHRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%

1/13 Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States -4.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day